- Home
- EQ
as 12-20-2024 3:35pm EST
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 24.8M | IPO Year: | 2018 |
| Target Price: | $5.00 | AVG Volume (30 days): | 117.7K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.56 - $3.25 | Next Earning Date: | 11-13-2024 |
| Revenue: | $45,914,000 | Revenue Growth: | 7.70% |
| Revenue Growth (this year): | 4.76% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Equillium Inc. (EQ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Keyes Jason A | EQ | Chief Financial Officer | Nov 14 '24 | Sell | $0.70 | 10,000 | $7,000.00 | 47,720 | |
| Zedelmayer Christine | EQ | Sr. Vice President and COO | Oct 28 '24 | Sell | $1.25 | 15,000 | $18,750.00 | 135,246 | |
| Tom Penny | EQ | Principal Accounting Officer | Oct 25 '24 | Sell | $1.25 | 3,518 | $4,397.50 | 9,368 | |
| Keyes Jason A | EQ | Chief Financial Officer | Sep 26 '24 | Sell | $0.81 | 10,000 | $8,100.00 | 47,720 |
Latest Equillium Inc. News
EQ Breaking Stock News: Dive into EQ Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
Business Wire
a month ago
Equillium to Present at the Stifel Healthcare Conference
Business Wire
a month ago
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer
Zacks
2 months ago
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth
MT Newswires
2 months ago
Sector Update: Health Care Stocks Softer Late Afternoon
MT Newswires
2 months ago
Top Midday Decliners
Zacks
2 months ago
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
Business Wire
2 months ago
Equillium Maintains Rights to Itolizumab Following Ono Partnership
Compare EQ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EQ Equillium Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.